An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(3), P. 490 - 495

Published: Jan. 19, 2022

Language: Английский

---

Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance

Journal of Chemical Information and Modeling, Journal Year: 2022, Volume and Issue: 62(2), P. 412 - 422

Published: Jan. 6, 2022

The latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron (B.1.1.529) has ushered panic responses around the world due to its contagious and vaccine escape mutations. essential infectivity antibody resistance of SARS-CoV-2 are determined by mutations on spike (S) protein receptor-binding domain (RBD). However, a complete experimental evaluation might take weeks or even months. Here, we present comprehensive quantitative analysis Omicron's infectivity, breakthrough, resistance. An artificial intelligence (AI) model, which been trained with tens thousands data extensively validated results SARS-CoV-2, reveals that may be over 10 times more than original virus about 2.8 as infectious Delta variant. On basis 185 three-dimensional (3D) structures antibody-RBD complexes, unveil have an 88% likelihood current vaccines. U.S. Food Drug Administration (FDA)-approved monoclonal antibodies (mAbs) from Eli Lilly seriously compromised. also diminish efficacy mAbs AstraZeneca, Regeneron mAb cocktail, Celltrion, Rockefeller University. impacts GlaxoSmithKline's sotrovimab appear mild. Our work calls for new strategies develop next generation mutation-proof vaccines antibodies.

Language: Английский

---

The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant

Journal of Medical Virology, Journal Year: 2022, Volume and Issue: 94(6), P. 2376 - 2383

Published: Feb. 4, 2022

Recently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) was first identified in Botswana November 2021. It reported to World Health Organization (WHO) on 24. On 26, 2021, according advice of scientists who are part WHO's Technical Advisory Group SARS-CoV-2 Virus Evolution (TAG-VE), WHO defined strain as a concern (VOC) and named it Omicron. Compared other four VOCs (Alpha, Beta, Gamma, Delta), most highly mutated strain, with 50 mutations accumulated throughout genome. The contains at least 32 spike protein, which twice many Delta variant. Studies have shown that carrying can increase infectivity immune escape compared early wild-type VOCs. is becoming dominant countries worldwide brings new challenges preventing controlling disease 2019 (COVID-19). current review article aims analyze summarize information data about biological characteristics amino acid mutations, epidemic characteristics, escape, vaccine reactivity variant, hoping provide scientific reference for monitoring, prevention, development strategies

Language: Английский

---

Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission

Reviews in Medical Virology, Journal Year: 2022, Volume and Issue: 32(5)

Published: July 20, 2022

Abstract The first dominant SARS‐CoV‐2 Omicron variant BA.1 harbours 35 mutations in its Spike protein from the original that emerged late 2019. Soon after discovery, rapidly to become worldwide and has since evolved into several variants. is of major public health concern owing high infectivity antibody evasion. This review article examines theories have been proposed on evolution including zoonotic spillage, infection immunocompromised individuals cryptic spread community without being diagnosed. Added complexity Omicron's are multiple reports recombination events occurring between co‐circulating variants with Delta other such as XE. Current literature suggests combination novel resulted having higher than Wuhan‐Hu‐1 variant. However, severity believed be less reduced syncytia formation lower multiplication human lung tissue. Perhaps most challenging studies indicate efficacy available vaccines against (8–127 times reduction) compared administration booster vaccine, however, compensates reduction improves by 12–35 fold. Concerningly though, broadly neutralising monoclonal antibodies, those approved FDA for therapeutic use previous variants, mostly ineffective exception Sotrovimab recent suggest BA.2 also resistant Sotrovimab. Currently two new BA.4 BA.5 emerging reported more transmissible immunity generated antibodies. As will likely continue emerge it important evolution, biological consequences mutations, existing well understood.

Language: Английский

---

Population Immunity and Covid-19 Severity with Omicron Variant in South Africa

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 386(14), P. 1314 - 1326

Published: Feb. 23, 2022

The B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng province, South Africa. Data regarding the seroprevalence SARS-CoV-2 IgG before fourth wave disease 2019 (Covid-19), which omicron dominant, are needed.

Language: Английский

---

Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic

Environmental Research, Journal Year: 2022, Volume and Issue: 209, P. 112816 - 112816

Published: Jan. 29, 2022

Language: Английский

---

Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies

Journal of Infection and Public Health, Journal Year: 2022, Volume and Issue: 16(1), P. 4 - 14

Published: Nov. 19, 2022

Newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are continuously posing high global public health concerns and panic resulting in waves disease 2019 (COVID-19) pandemic. Depending on the extent genomic variations, mutations adaptation, few gain ability to spread quickly across many countries, acquire higher virulency cause disease, morbidity mortality. These have been implicated lessening efficacy current COVID-19 vaccines immunotherapies break-through viral infections vaccinated individuals recovered patients. Altogether, these could hinder protective herd immunity be achieved through ongoing progressive vaccination. Currently, only variant interest SARS-CoV-2 is Omicron that was first identified South Africa. In this review, we present overview with a special focus variant, its lineages hybrid variants. We discuss hypotheses origin, genetic change underlying molecular mechanism behind transmissibility immune escape variant. Major related including available immunotherapeutics vaccines, transmissibility, severity, mortality discussed. last part, challenges strategies counter amid pandemic presented.

Language: Английский

---

Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants

The Journal of Infectious Diseases, Journal Year: 2022, Volume and Issue: 227(3), P. 344 - 352

Published: Oct. 10, 2022

Four severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants predominated in the United States since 2021. Understanding disease severity related to different SARS-CoV-2 remains limited.Viral genome analysis was performed on clinical isolates circulating March 2021 through 2022 Cleveland, Ohio. Major were correlated with and patient outcomes.In total 2779 patients identified either Alpha (n 1153), Gamma 122), Delta 808), or Omicron 696) selected for analysis. No difference frequency of hospitalization, intensive care unit (ICU) admission, death found among Alpha, Gamma, variants. However, infection significantly less likely be admitted hospital, require oxygen, admission ICU (2 12.8, P .001; 21.6, .002; 9.6, .01, respectively). In whose vaccination status known, a substantial number had breakthrough infections (218/808 [26.9] 513/696 [73.7], infections, hospitalization rate similar regardless variant by multivariate between subvariants BA.1 BA.2.Disease associated is comparable while are severe. Breakthrough more common infection.

Language: Английский

---

Percentage of Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A Systematic Review and Meta-Analysis

Vaccines, Journal Year: 2022, Volume and Issue: 10(7), P. 1049 - 1049

Published: June 30, 2022

Background: Asymptomatic infections are potential sources of transmission for coronavirus disease 2019, especially during the epidemic SARS-CoV-2 Omicron variant. We aimed to assess percentage asymptomatic among variant-positive individuals detected by gene sequencing or specific polymerase chain reaction (PCR). Methods: searched PubMed, EMBASE, and Web Science from 26 November 2021 13 April 2022. This meta-analysis was conducted following Preferred Reporting Items Systematic Reviews Meta-Analyses guidelines registered with PROSPERO (CRD42022327894). Three researchers independently extracted data two assessed quality using pre-specified criteria. The pooled 95% confidence interval (CI) estimated random-effects models. Results: Our included eight eligible studies, covering 7640 2190 infections. 32.40% (95% CI: 25.30−39.51%) individuals, which higher in population developing countries (38.93%; 19.75−58.11%), vaccine coverage ≥ 80% (35.93%; 25.36−46.51%), a travel history (40.05%; 7.59−72.51%), community infection (37.97%; 10.07−65.87%), median age < 20 years (43.75%; 38.45−49.05%). Conclusion: In this systematic review meta-analysis, individuals. people who were vaccinated, young (median years), had history, infected outside clinical setting (community infection) percentages Screening is required prevent clustered epidemics sustained caused variants, regions that have successfully controlled SARS-CoV-2.

Language: Английский

---

SARS‐CoV‐2 Omicron variant: Immune escape and vaccine development

MedComm, Journal Year: 2022, Volume and Issue: 3(1)

Published: March 1, 2022

Abstract New genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) constantly emerge through unmitigated spread the virus in ongoing Coronavirus disease 2019 pandemic. Omicron (B.1.1.529), latest variant concern (VOC), has so far shown exceptional and infectivity established itself as dominant recent months. The SARS‐CoV‐2 spike glycoprotein is a key component for recognition binding to host cell angiotensin‐converting enzyme receptors. harbors cluster substitutions/deletions/insertions, more than 30 mutations are located spike. Some noticeable mutations, including K417N, T478K, N501Y, P681H, shared with previous VOCs Alpha, Beta, Gamma, or Delta have been proven be associated higher transmissibility, viral infectivity, immune evasion potential. Studies revealed that partially resistant neutralizing activity therapeutic antibodies convalescent sera, which poses significant challenges clinical effectiveness current vaccines antibodies. We provide comprehensive analysis summary epidemiology escape mechanisms variant. also suggest some strategies against This review, therefore, aims information further research efforts prevent contain impact new during

Language: Английский

---